Kristie L. Kahl | Authors

October 24, 2022

An extended follow-up of the phase 3 COSMIC-311 trial supported the use of cabozantinib to treat patients with radioiodine-refractory differentiated thyroid cancer, irrespective of the duration of prior lenvatinib received.

October 22, 2022

Psychiatric history may be an important factor for physicians to consider when counseling patients on their treatment options with thyroid cancer, according to a retrospective chart review.

October 21, 2022

Investigators found that higher body mass index is associated with more aggressive differentiated thyroid carcinoma tumors, as well as an increased risk for worse clinical outcomes, with patients with a BMI above 28.4 being at a higher risk.

October 21, 2022

A real-world retrospective patient chart review showed a 72.4% physician-reported best overall response, confirming the agent’s clinical efficacy to treat patients with RAI-refractory differentiated thyroid cancer.

October 21, 2022

A study found that after their first primary malignancy diagnosis, cancer survivors are at a significantly increased risk for secondary primary thyroid cancer, with other half of cases occurring in the first 3 years.

October 21, 2022

A prospective study of blood samples confirmed the immune-modulatory effect of lenvatinib with a significant increase in the peripheral natural killer cells among patients with advanced thyroid cancer.